An In Depth Cardiovascular Study of Lisdexamfetamine (LDX; Vyvanse) in Healthy and Treated Hypertensive Adults With Attention Deficit Hyperactivity Disorder (ADHD).
Phase of Trial: Phase IV
Latest Information Update: 21 Sep 2012
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacodynamics
- 25 Mar 2011 Actual end date changed from Dec 2011 to Mar 2011 as reported by ClinicalTrials.gov.
- 25 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jan 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.